BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11479231)

  • 1. Genetic analysis of early- versus late-stage ovarian tumors.
    Shridhar V; Lee J; Pandita A; Iturria S; Avula R; Staub J; Morrissey M; Calhoun E; Sen A; Kalli K; Keeney G; Roche P; Cliby W; Lu K; Schmandt R; Mills GB; Bast RC; James CD; Couch FJ; Hartmann LC; Lillie J; Smith DI
    Cancer Res; 2001 Aug; 61(15):5895-904. PubMed ID: 11479231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization.
    Shridhar V; Sen A; Chien J; Staub J; Avula R; Kovats S; Lee J; Lillie J; Smith DI
    Cancer Res; 2002 Jan; 62(1):262-70. PubMed ID: 11782386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
    Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
    Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
    Blaveri E; Brewer JL; Roydasgupta R; Fridlyand J; DeVries S; Koppie T; Pejavar S; Mehta K; Carroll P; Simko JP; Waldman FM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7012-22. PubMed ID: 16203795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
    Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
    Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of 20q13.2 copy number changes with the advanced stage of ovarian cancer-tissue microarray analysis.
    Dimova I; Yosifova A; Zaharieva B; Raitcheva S; Doganov N; Toncheva D
    Eur J Obstet Gynecol Reprod Biol; 2005 Jan; 118(1):81-5. PubMed ID: 15596278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of gene expression in early-stage ovarian cancer.
    Marchini S; Mariani P; Chiorino G; Marrazzo E; Bonomi R; Fruscio R; Clivio L; Garbi A; Torri V; Cinquini M; Dell'Anna T; Apolone G; Broggini M; D'Incalci M
    Clin Cancer Res; 2008 Dec; 14(23):7850-60. PubMed ID: 19047114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
    Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
    Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Risch HA; Puopolo M; Yu H
    Clin Cancer Res; 2006 Feb; 12(4):1208-14. PubMed ID: 16489075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
    Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
    Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for genes associated with ovarian cancer prognosis.
    Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
    Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
    Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
    Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors.
    Helou K; Padilla-Nash H; Wangsa D; Karlsson E; Osterberg L; Karlsson P; Ried T; Knutsen T
    Cancer Genet Cytogenet; 2006 Oct; 170(1):1-8. PubMed ID: 16965948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.
    Suzuki S; Moore DH; Ginzinger DG; Godfrey TE; Barclay J; Powell B; Pinkel D; Zaloudek C; Lu K; Mills G; Berchuck A; Gray JW
    Cancer Res; 2000 Oct; 60(19):5382-5. PubMed ID: 11034075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.
    Jazaeri AA; Lu K; Schmandt R; Harris CP; Rao PH; Sotiriou C; Chandramouli GV; Gershenson DM; Liu ET
    Mol Carcinog; 2003 Feb; 36(2):53-9. PubMed ID: 12557260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.
    Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Schwartz P; Yu H
    Gynecol Oncol; 2006 Dec; 103(3):990-5. PubMed ID: 16859738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.